GlassScriptPhysician profile
Emma Jane Conroy
NPI 1538846472
$2,500.62
in general payments reported to CMS, 2019-2025
25 companies · $1,044 in 2025
The $1,044 reported for 2025 was more than what 81% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $479 · 2024: $978 · 2025: $1,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,500.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $257.30 | 2023-2025 | Wegovy, Sogroya, Ozempic |
| Amgen INC. | $229.05 | 2023-2025 | Tepezza, Repatha, Prolia |
| Lilly USA, LLC | $224.98 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Beta Bionics, INC. | $217.04 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Tandem Diabetes Care, INC. | $190.85 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $175.05 | 2023-2025 | |
| Medtronic, INC. | $165.73 | 2023-2024 | Minimed 780g |
| Sequel Med Tech, LLC | $126.07 | 2025 | Twiist |
| Tg Therapeutics, INC. | $124.99 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.92 | 2023-2025 | Jardiance |
| Insulet Corporation | $109.35 | 2023-2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $68.82 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $66.54 | 2024-2025 | Isturisa, Signifor Lar |
| Ibsa Pharma INC. | $58.94 | 2024-2025 | Licart, Tirosint, Flector |
| Ascendis Pharma Endocrinology INC | $54.05 | 2024-2025 | Yorvipath |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $51.78 | 2023-2024 | Tymlos |
| Mannkind Corporation | $49.12 | 2024-2025 | |
| Dexcom, INC. | $44.68 | 2023 | Dexcom G6 Transmitter |
| Amphastar Pharmaceuticals, INC. | $42.58 | 2025 | |
| Ascensia Diabetes Care US INC. | $32.44 | 2023 | |
| Abbott Laboratories | $26.84 | 2025 | Freestyle Libre 3 |
| Almatica Pharma LLC | $24.06 | 2025 | Teriparatide |
| Amneal Pharmaceuticals LLC | $20.61 | 2024 | Unithroid |
| Corcept Therapeutics | $15.42 | 2025 | Korlym |
| Cequr Corporation | $5.41 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Conroy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.